Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study - Wikidata - wikimedia - TriplyDB

Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study

Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study

http://www.wikidata.org/entity/Q36199558

about

Phosphate control in end-stage renal disease: barriers and opportunities Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients.PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism Risk of Band Keratopathy in Patients with End-Stage Renal Disease.Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.Cinacalcet and Clinical Outcomes in Dialysis.Clinical features of CKD-MBD in Japan: cohort studies and registry.Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.The cardiothoracic ratio and all-cause and cardiovascular disease mortality in patients undergoing maintenance hemodialysis: results of the MBD-5D study.The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan.A Japanese approach for CKD-MBD A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.

P2860

Q26853372-3CCE399A-EA29-4858-9958-2596CE14B434 Q34828835-DB8D5830-DD6C-42D2-B99D-06E8603B60E2 Q35391160-52E92569-53F0-404B-B323-E716D8E01D35 Q36793098-6D810AE1-185D-499C-B289-89D7467798B0 Q37039937-787BD8D2-66C4-4E3D-9233-06F2965E8A2A Q38092144-378CC166-C0E4-459A-A4D1-B87C2B8561F1 Q38565049-F08F5277-D2BD-4BD3-9ECC-1062224237E8 Q38784139-7F027881-1DAF-484E-B674-5D28CE2F3AD1 Q38824573-7D69BF86-C210-4BE0-921B-3EA6C893C3DC Q39946556-266D63EA-45E0-4BBE-AFC7-1F5F4E634D6B Q40200123-F3C010A3-7719-4E9E-980F-10498F6E8095 Q42672060-0DC606D5-1B4A-495D-B57B-292324A65A04 Q42727650-969923BA-A566-4527-A21A-6925FD9AAF1E Q42727652-0B9E75F0-DB5A-44C4-9315-C44290B23D17 Q52722043-F98BC89E-C190-47C3-ACAA-B34B0184C22B

P2860

Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study

http://www.wikidata.org/entity/Q36199558

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Prescription patterns and mine ...... results from the MBD-5D study

@ast

Prescription patterns and mine ...... results from the MBD-5D study

@en

type

label

Prescription patterns and mine ...... results from the MBD-5D study

@ast

Prescription patterns and mine ...... results from the MBD-5D study

@en

prefLabel

Prescription patterns and mine ...... results from the MBD-5D study

@ast

Prescription patterns and mine ...... results from the MBD-5D study

@en

P1433

Q36199558-DC43D28E-58DA-4DC1-A614-65B9B6C579C8

P1476

Q36199558-26B8ABE2-AF63-4EF2-ABA5-9CCEB653F447

P2093

Q36199558-56A7CD7B-4D96-4F68-B087-5625D41AA19B

Q36199558-672DE50F-7B93-4F15-9A33-5B4D402E1755

Q36199558-6CF4E4A6-2A84-446F-AA3D-3B2564AAE56E

Q36199558-7B867E49-D6AA-4130-A0C6-222FA57C0C85

Q36199558-827BE588-6A85-450D-B8E0-F25AB99E5454

Q36199558-EC72E0EC-7AED-4F46-A69A-EC8D33126505

P2860

Q36199558-09960ADD-AC3F-4E85-90F4-31FD96219C68

Q36199558-0F939AAF-CD8E-4ADE-8F7C-1B8038FDF0AF

Q36199558-13BC8518-3190-4FA6-8E54-30B00DBDC11C

Q36199558-14F34037-D530-4846-AAFD-4638B2851D98

Q36199558-15237A83-1404-4B4B-997B-F26D2BB95809

Q36199558-1C078560-0066-4083-9394-AFD7B23420A7

Q36199558-2DF6D32B-D6C7-496D-9D1C-DA35BA96610E

Q36199558-2F96D28F-BEF2-4872-85B9-A479C6F47494

Q36199558-31123D26-F0AD-46D7-8ECB-474E408774BB

Q36199558-53D4807F-6BED-4E84-98B1-6B76CC55B5B4

P304

Q36199558-57B38E0F-BC95-49D7-80CE-DBA59650D8F9

P31

Q36199558-0FE10A1B-6AA2-4D3A-B6CD-8135AC4CBF8F

P356

Q36199558-F54C7A6E-D436-4BF8-9FCB-9BFDE591A137

P433

Q36199558-1F04DBE3-1B8F-4905-AE01-4525DDFA874C

P478

Q36199558-AB738F0B-399C-466B-982C-2311CDA6AE25

P50

Q36199558-5E9E903D-F7F7-47F4-9A80-FC666273C65B

Q36199558-8C69FF65-058A-4A75-8B87-E183782E3DD7

P577

Q36199558-1988E466-E81D-415E-97D3-62081453C1CA

P698

Q36199558-5EDB4D25-F557-4134-820E-E92C7845256D

P932

Q36199558-AC24794F-C96D-413B-8D31-10F2E8379ED3

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Prescription patterns and mine ...... results from the MBD-5D study

@en

P2093

Kiyoshi Kurokawa

http://www.w3.org/2001/XMLSchema#string

Shingo Fukuma

http://www.w3.org/2001/XMLSchema#string

Shunichi Fukuhara

http://www.w3.org/2001/XMLSchema#string

Tadao Akizawa

http://www.w3.org/2001/XMLSchema#string

Takuhiro Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Onishi

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical analysis of correlated data using generalized estimating equations: an orientation.

An overview of methods for the analysis of longitudinal data.

Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D.

Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.

Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease.

The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006

P304

1473-1480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.13081211

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Takeshi Hasegawa

Masafumi Fukagawa

P577

2012-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22822017

http://www.w3.org/2001/XMLSchema#string

P932

3430956

http://www.w3.org/2001/XMLSchema#string